Table 1.
Baseline patient characteristics n (%)
| Characteristic | Total patients, n = 134 |
| Male sex | 89 (66.4) |
| Age, yr, mean ± SD | 63.1 ± 10.4 |
| Etiology of primary hepatic tumor | |
| Viral hepatitis B infection | 73 (54.5) |
| Viral hepatitis C infection | 24 (17.9) |
| Alcohol consumption | 22 (16.4) |
| Others | 9 (6.7) |
| Viral infection + alcohol consumption | 6 (4.5) |
| Decompensated cirrhosis | 51 (38.1) |
| Child-Pugh class (A/B/C) | 93 (69.4)/39 (29.1)/2 (1.5) |
| Portal hypertension (present) | 93 (69.4) |
| Tumor related characteristics | |
| Tumor maximal diameter, median (range) | 2.6 (1.0-12.7) |
| Tumor number (single/multiple) | 88 (65.7)/46 (34.3) |
| Portal vein thrombosis (present) | 9 (6.7) |
| Well defined/infiltrating | 131 (97.8)/3 (2.2) |
| Ruptured HCC | 4 (3.0) |
| Tumor staging (AJCC 7th edition) | |
| Stage I | 84 (62.7) |
| Stage II | 36 (26.9) |
| Stage IIIA/IIIB/IIIC | 7 (5.2)/5 (3.7)/- |
| Stage IVA/IVB | -/2 (1.5) |
| Laboratory finding | |
| Total bilirubin, mg/dL, median (range) | 0.90 (0.20-5.20) |
| Prothrombin time, s, mean ± SD | 13.41 ± 2.10 |
| Albumin, mg/dL, mean ± SD | 3.61 ± 0.53 |
| TACE no. to CR (1/2/3/≥ 4) | 107/19/5/3 (79.9/14.2/3.7/2.2) |
AJCC: American Joint Committee on Cancer; HCC: Hepatocellular carcinoma; SD: Standard deviation; TACE: Transcatheter arterial chemoembolization; CR: Complete response.